Page 3 - Josh Mandel Brehm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
News provided by
Share this article
 a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted orphan drug designation for VO659, Vico s investigational antisense oligonucleotide therapy for the treatment of Spinocerebellar Ataxia (SCA). The orphan designation was based on a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Vico previously received orphan drug designation for VO659 in Huntington Disease.
Spinocerebellar Ataxias ....

Noord Holland , Spinocerebellar Ataxias , Judith Van Deutekom , Rupert Sandbrink , Gail Mandel , Pureos Bioventures , Luc Dochez , Gertjan Bartlema , Josh Mandel Brehm , Committee For Orphan Medicinal Products , European Union , European Medicines Agency , European Commission , Lifespring Life Sciences Communication , Spinocerebellar Ataxia , Orphan Medicinal Products , Chief Medical Officer , Chief Business Officer , Spring Life Sciences Communication , Huntington Disease , Life Science Partners , Kurma Partners , Droia Genetic Disease , Polaris Partners , Vico Therapeutics , நூற்த் ஹாலண்ட் ,